Cargando…

Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection

IMPORTANCE: Tenofovir disoproxil and entecavir are both commonly used first-line antiviral treatments, but their comparative recurrence and overall survival (OS) benefits remain unclear. OBJECTIVE: To explore differences of tenofovir disoproxil vs entecavir in recurrence-free survival (RFS) and OS a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Pengpeng, Wang, Yuanyuan, Yu, Jian, Yu, Judian, Tao, Qifei, Zhang, Jinwei, Lau, Wan Yee, Zhou, Weiping, Huang, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618847/ https://www.ncbi.nlm.nih.gov/pubmed/37906195 http://dx.doi.org/10.1001/jamanetworkopen.2023.40353

Ejemplares similares

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
por: Huang, Yan, et al.
Publicado: (2022)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
por: Yang, Young-Mo, et al.
Publicado: (2017)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis
por: Tan, Darren Jun Hao, et al.
Publicado: (2022)

Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation
por: Yang, Jianming, et al.
Publicado: (2023)

Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA
por: Shi, Hong, et al.
Publicado: (2016)

HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis
por: Xu, Xiaolan, et al.
Publicado: (2023)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Effects of viral load on tenofovir vs. entecavir efficacy in recurrence prevention of hepatitis B virus-related hepatocellular carcinoma
por: Qi, Weili, et al.
Publicado: (2023)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation
por: Hu, Zili, et al.
Publicado: (2022)

Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy
por: Shen, Junyi, et al.
Publicado: (2022)

3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
por: Hou, Jinlin, et al.
Publicado: (2021)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020)

Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis
por: Cheung, Ka Shing, et al.
Publicado: (2020)

HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir
por: Yasutake, Yoshiaki, et al.
Publicado: (2018)

Tenofovir over Entecavir on Hepatocellular Carcinoma Prevention: Potential Mechanisms and Suitable Population
por: Huang, Yongfa, et al.
Publicado: (2022)

Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis
por: Lee, Hyo-Young, et al.
Publicado: (2019)

868: PREVENTING HEPATCELLULAR CARCINOMA WITH TENOFOVIR VS ENTECAVIR: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF PROPENSITY SCORE MATCHED STUDIES
por: Tan, Darren J., et al.
Publicado: (2022)

Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial
por: Linye, He, et al.
Publicado: (2023)

Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients
por: Cho, Eun Ju, et al.
Publicado: (2015)

Virologic Response and Safety of Tenofovir Versus Entecavir in Treatment-Naïve Chronic Hepatitis B patients
por: Yu, Hyung Min, et al.
Publicado: (2015)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)

No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis
por: Yuan, Jie, et al.
Publicado: (2021)

Letter to the Editor: Entecavir Treatment Restores the Anti‐HBV Immune response?
por: Beudeker, Boris J.B., et al.
Publicado: (2021)

Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice
por: Qi, Ruoyao, et al.
Publicado: (2023)

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
por: Kim, David Sooik, et al.
Publicado: (2019)

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
por: Huang, Chih-Wen, et al.
Publicado: (2023)

MicroRNAs Associated With HBV Infection And HBV-related HCC
por: Xie, Kun-Lin, et al.
Publicado: (2014)

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C
por: Yu, Jiao, et al.
Publicado: (2022)

Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B
por: Chang, Te-Sheng, et al.
Publicado: (2021)

Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir
por: Lim, Jung Hyun, et al.
Publicado: (2021)

HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons
por: Bihl, Florian, et al.
Publicado: (2015)

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
por: Kim, Jeong Han, et al.
Publicado: (2016)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
por: Jeon, Hee-Jeong, et al.
Publicado: (2017)

Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
por: Ha, Yeonjung, et al.
Publicado: (2020)

Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment
por: Ma, Te-Ling, et al.
Publicado: (2019)

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
por: Lee, Sung Won, et al.
Publicado: (2021)

Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse
por: Tseng, Tzu-Ning, et al.
Publicado: (2022)

Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B
por: Tang, Kaiyue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3bm09c92vob1eod5319862almg